Top-Rated StocksTop-RatedNYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $29.24 +1.02 (+3.62%) Closing price 03/14/2025 03:58 PM EasternExtended Trading$29.16 -0.08 (-0.26%) As of 03/14/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Biohaven Stock (NYSE:BHVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biohaven alerts:Sign Up Key Stats Today's Range$28.50▼$29.6550-Day Range$27.47▼$42.6752-Week Range$26.80▼$60.46Volume653,834 shsAverage Volume1.08 million shsMarket Capitalization$2.98 billionP/E RatioN/ADividend YieldN/APrice Target$63.15Consensus RatingBuy Company OverviewBiohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Read More… Remove Ads Biohaven Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 73% of companies evaluated by MarketBeat, and ranked 288th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiohaven has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 5.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.75% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Biohaven has recently decreased by 3.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.75% of the float of Biohaven has been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Biohaven has recently decreased by 3.94%, indicating that investor sentiment is improving. News and Social Media1.7 / 5News Sentiment0.12 News SentimentBiohaven has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Biohaven this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,038,629.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Stock News HeadlinesBiohaven Ltd. (NYSE:BHVN) Director John W. Childs Buys 32,700 SharesMarch 6, 2025 | insidertrades.comPositive Outlook for Biohaven Ltd. Amid Promising Developments and FDA Priority ReviewMarch 10, 2025 | tipranks.comA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.March 15, 2025 | Chaikin Analytics (Ad)Morgan Stanley Issues Pessimistic Forecast for Biohaven (NYSE:BHVN) Stock PriceMarch 10, 2025 | americanbankingnews.comBiohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025March 9, 2025 | insidermonkey.comCantor Fitzgerald Reduces Earnings Estimates for BiohavenMarch 8, 2025 | americanbankingnews.comMorgan Stanley verlaagt koersdoel Biohaven-aandeel naar $ 63 van $ 69March 7, 2025 | nl.investing.comJPMorgan Chase & Co. Lowers Biohaven (NYSE:BHVN) Price Target to $68.00March 7, 2025 | americanbankingnews.comSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $37.35 on January 1st, 2025. Since then, BHVN shares have decreased by 21.7% and is now trading at $29.2410. View the best growth stocks for 2025 here. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings data on Monday, March, 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by $0.29. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Top institutional shareholders of Biohaven include Vanguard Group Inc. (8.32%), Janus Henderson Group PLC (6.91%), Stifel Financial Corp (6.49%) and Suvretta Capital Management LLC (5.56%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten, George C Clark and Irina Antonijevic. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings3/03/2025Today3/15/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CIK1689813 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Stock Price Target$63.15 High Stock Price Target$76.00 Low Stock Price Target$54.00 Potential Upside/Downside+116.0%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($9.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-408,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-225.12% Return on Assets-158.89% Debt Debt-to-Equity RatioN/A Current Ratio2.89 Quick Ratio2.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.34 per share Price / Book5.48Miscellaneous Outstanding Shares102,054,000Free Float84,942,000Market Cap$2.98 billion OptionableOptionable Beta1.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:BHVN) was last updated on 3/15/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.